Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,567.00-0.24%ETH$2,697.69-0.48%GOLD$4,194.10+0.17%OIL$90.00+0.63%
Smart Investors Daily
SID Premium
AB

NASDAQ · ABUS

Arbutus Biopharma Corporation

Healthcare · Biotechnology

$4.67

Down-$0.19 (-4.07%)

Updated Oct 7, 2026, 12:01 AM

SID Score

3.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
896.23M
P/E ratio
-21.14
Dividend yield
0.00%
52-week range
$4.01 – $5.45
Volume
6.18M
Avg. volume
1.58M

Price performance · ABUS

ABUS price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 5, 2026

ABUS closed at $4.67 after 20 trading sessions, down 9.85% for the selected period.

Last close
$4.67
Period change
-9.85%
Period low
$4.45
Period high
$5.18
Daily close
View OHLC price history
ABUS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 5, 2026$4.45$4.80$4.41$4.676.18M
Oct 2, 2026$4.55$4.68$4.375$4.458.99M
Oct 1, 2026$4.77$4.775$4.51$4.5616.12M
Sep 30, 2026$4.675$4.95$4.675$4.7816.88M
Sep 29, 2026$4.86$4.89$4.67$4.6917.56M
Sep 28, 2026$4.84$4.88$4.80$4.8611.67M
Sep 25, 2026$4.89$4.93$4.84$4.8516.88M
Sep 24, 2026$4.85$4.885$4.8009$4.886.26M
Sep 23, 2026$5.01$5.02$4.84$4.8510.84M
Sep 22, 2026$5.02$5.05$4.995$5.0110.49M
Sep 21, 2026$5.03$5.07$4.99$5.004.56M
Sep 18, 2026$5.04$5.06$4.98$5.016.46M
Sep 17, 2026$5.10$5.10$5.04$5.072.72M
Sep 16, 2026$5.06$5.0891$5.02$5.054.01M
Sep 15, 2026$5.11$5.15$5.03$5.064.05M
Sep 14, 2026$5.12$5.16$5.095$5.133.8M
Sep 11, 2026$5.17$5.175$5.11$5.121.85M
Sep 10, 2026$5.11$5.165$5.10$5.122.45M
Sep 9, 2026$5.16$5.23$5.125$5.175.51M
Sep 8, 2026$5.10$5.20$5.08$5.185.29M

Latest ABUS news

The latest Smart Investors Daily articles mentioning ABUS.

Stock researchCompany · Overview

ABUS research

Overview

Company profile and research snapshot.

Company profile

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$8.50
Implied upside
—
Analysts
—
ABUS recent ratings
DateFirmRatingTarget
Nov 14, 2025Chardan CapitalBuy—
Aug 11, 2025Chardan CapitalBuy—
Mar 28, 2025Chardan CapitalBuy—
Jan 21, 2025HC Wainwright & Co.Buy—
Nov 20, 2024Chardan CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 30, 2026

Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer

WARMINSTER, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the preliminary results of its tender offer (the “Offer”) to purchase for cancellation up to US$230 million in value of its common shares (the “Shares”). The Offer proceeded by way of a modified Dutch auction, which had a tender price range from US$5.00 per Share to US$5.75 per Shar

Yahoo · Aug 24, 2026

Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share

WARMINSTER, Pa., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the commencement of a modified “Dutch Auction” tender offer to purchase for cancellation up to US$230 million in value of its common shares (the “Shares”) at a price of not less than US$5.00 and not more than US $5.75 per Share, less any applicable withholding taxes and without inter

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By